Anti-IDE antibodies and uses of same
Isolated anti-IDE antibodies are provided. Each of the antibodies comprise an antigen recognition domain comprising the indicated CDR amino acid sequences. Methods of producing same, methods of using same, pharmaceutical compositions comprising same and articles of manufacture are also provided.
1 . An isolated antibody comprising an antigen recognition region, which specifically binds insulin-degrading enzyme (IDE), wherein said antigen recognition domain comprises complementarity determining region (CDR) amino acid sequences as set forth in
SEQ ID NOs: 36 (CDR1), 38 (CDR2) and 40 (CDR3), being sequentially arranged from N to C on a heavy chain of said antibody; and 44 (CDR1), 46 (CDR2) and 48 (CDR3), being sequentially arranged from N to C on a light chain of said antibody.
2 . A pharmaceutical composition comprising as an active ingredient the antibody of claim 1 and a pharmaceutically acceptable carrier.
3 . A method for treating a disease associated with an IDE activity selected from the group consisting of diabetes and Parkinson's disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the antibody of claim 1 , thereby treating the disease in the subject.
4 . The method of claim 3 , further comprising administering to said subject a therapeutic agent for treating said disease.
5 . The method of claim 3 , wherein said subject has a level of IDE above a predetermined threshold in a biological sample as compared to a control biological sample.
6 . The antibody of claim 1 , being an intact IgG antibody.
7 . An isolated polynucleotide comprising a nucleic acid sequence encoding an antibody comprising an antigen recognition region, which specifically binds insulin-degrading enzyme (IDE), wherein said antigen recognition domain comprises complementarity determining region (CDR) amino acid sequences as set forth in SEQ ID NOs: 36 (CDR1), 38 (CDR2) and 40 (CDR3), being sequentially arranged from N to C on a heavy chain of said antibody; and 44 (CDR1), 46 (CDR2) and 48 (CDR3), being sequentially arranged from N to C on a light chain of said antibody.
8 . The isolated polynucleotide of claim 7 , wherein nucleic acid sequences encoding said CDR amino acid sequences are as set forth in
SEQ ID NOs: 35, 37, 39, 43, 45 and 47.
9 . A method of producing an anti-insulin-degrading enzyme (IDE) antibody, the method comprising expressing in a host cell the polynucleotide of claim 7 .
10 . The method of claim 9 , comprising isolating the antibody.
11 . A host cell expressing an antibody comprising an antigen recognition region, which specifically binds insulin-degrading enzyme (IDE), wherein said antigen recognition domain comprises complementarity determining region (CDR) amino acid sequences as set forth in SEQ ID NOs: 36 (CDR1), 38 (CDR2) and 40 (CDR3), being sequentially arranged from N to C on a heavy chain of said antibody; and 44 (CDR1), 46 (CDR2) and 48 (CDR3), being sequentially arranged from N to C on a light chain of said antibody.